127 related articles for article (PubMed ID: 37866634)
1. The molecular basis of dapsone activation of CYP2C9-catalyzed nonsteroidal anti-inflammatory drug oxidation.
Nair PC; Burns K; Chau N; McKinnon RA; Miners JO
J Biol Chem; 2023 Dec; 299(12):105368. PubMed ID: 37866634
[TBL] [Abstract][Full Text] [Related]
2. Activation of CYP2C9-mediated metabolism by a series of dapsone analogs: kinetics and structural requirements.
Hutzler JM; Kolwankar D; Hummel MA; Tracy TS
Drug Metab Dispos; 2002 Nov; 30(11):1194-200. PubMed ID: 12386124
[TBL] [Abstract][Full Text] [Related]
3. Differential activation of CYP2C9 variants by dapsone.
Hummel MA; Dickmann LJ; Rettie AE; Haining RL; Tracy TS
Biochem Pharmacol; 2004 May; 67(10):1831-41. PubMed ID: 15130760
[TBL] [Abstract][Full Text] [Related]
4. Dapsone activation of CYP2C9-mediated metabolism: evidence for activation of multiple substrates and a two-site model.
Hutzler JM; Hauer MJ; Tracy TS
Drug Metab Dispos; 2001 Jul; 29(7):1029-34. PubMed ID: 11408370
[TBL] [Abstract][Full Text] [Related]
5. Polymorphic variants (CYP2C9*3 and CYP2C9*5) and the F114L active site mutation of CYP2C9: effect on atypical kinetic metabolism profiles.
Tracy TS; Hutzler JM; Haining RL; Rettie AE; Hummel MA; Dickmann LJ
Drug Metab Dispos; 2002 Apr; 30(4):385-90. PubMed ID: 11901091
[TBL] [Abstract][Full Text] [Related]
6. Effector-mediated alteration of substrate orientation in cytochrome P450 2C9.
Hummel MA; Gannett PM; Aguilar JS; Tracy TS
Biochemistry; 2004 Jun; 43(22):7207-14. PubMed ID: 15170358
[TBL] [Abstract][Full Text] [Related]
7. Activation of cytochrome P450 2C9-mediated metabolism: mechanistic evidence in support of kinetic observations.
Hutzler JM; Wienkers LC; Wahlstrom JL; Carlson TJ; Tracy TS
Arch Biochem Biophys; 2003 Feb; 410(1):16-24. PubMed ID: 12559973
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of atypical cytochrome P450 kinetics with two-substrate models: evidence that multiple substrates can simultaneously bind to cytochrome P450 active sites.
Korzekwa KR; Krishnamachary N; Shou M; Ogai A; Parise RA; Rettie AE; Gonzalez FJ; Tracy TS
Biochemistry; 1998 Mar; 37(12):4137-47. PubMed ID: 9521735
[TBL] [Abstract][Full Text] [Related]
9. Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development.
Zhou SF; Zhou ZW; Yang LP; Cai JP
Curr Med Chem; 2009; 16(27):3480-675. PubMed ID: 19515014
[TBL] [Abstract][Full Text] [Related]
10. Minimal in vivo activation of CYP2C9-mediated flurbiprofen metabolism by dapsone.
Hutzler JM; Frye RF; Korzekwa KR; Branch RA; Huang SM; Tracy TS
Eur J Pharm Sci; 2001 Aug; 14(1):47-52. PubMed ID: 11457649
[TBL] [Abstract][Full Text] [Related]
11. Structural dynamics of the cooperative binding of small inhibitors in human cytochrome P450 2C9.
Cai J; Shi R
J Mol Graph Model; 2022 Jun; 113():108151. PubMed ID: 35168147
[TBL] [Abstract][Full Text] [Related]
12. Substrate proton to heme distances in CYP2C9 allelic variants and alterations by the heterotropic activator, dapsone.
Hummel MA; Gannett PM; Aguilar J; Tracy TS
Arch Biochem Biophys; 2008 Jul; 475(2):175-83. PubMed ID: 18485885
[TBL] [Abstract][Full Text] [Related]
13. Polymorphic variants of CYP2C9: mechanisms involved in reduced catalytic activity.
Wei L; Locuson CW; Tracy TS
Mol Pharmacol; 2007 Nov; 72(5):1280-8. PubMed ID: 17686967
[TBL] [Abstract][Full Text] [Related]
14. Comparative studies on the catalytic roles of cytochrome P450 2C9 and its Cys- and Leu-variants in the oxidation of warfarin, flurbiprofen, and diclofenac by human liver microsomes.
Yamazaki H; Inoue K; Chiba K; Ozawa N; Kawai T; Suzuki Y; Goldstein JA; Guengerich FP; Shimada T
Biochem Pharmacol; 1998 Jul; 56(2):243-51. PubMed ID: 9698079
[TBL] [Abstract][Full Text] [Related]
15. Effect of CYP2C9 genetic polymorphism on the metabolism of flurbiprofen in vitro.
Wang L; Bao SH; Pan PP; Xia MM; Chen MC; Liang BQ; Dai DP; Cai JP; Hu GX
Drug Dev Ind Pharm; 2015; 41(8):1363-7. PubMed ID: 25144335
[TBL] [Abstract][Full Text] [Related]
16. Cytochromes P450, 1A2, and 2C9 are responsible for the human hepatic O-demethylation of R- and S-naproxen.
Miners JO; Coulter S; Tukey RH; Veronese ME; Birkett DJ
Biochem Pharmacol; 1996 Apr; 51(8):1003-8. PubMed ID: 8866821
[TBL] [Abstract][Full Text] [Related]
17. CYP2D6-CYP2C9 protein-protein interactions and isoform-selective effects on substrate binding and catalysis.
Subramanian M; Low M; Locuson CW; Tracy TS
Drug Metab Dispos; 2009 Aug; 37(8):1682-9. PubMed ID: 19448135
[TBL] [Abstract][Full Text] [Related]
18. Characterization of CYP2C19 and CYP2C9 from human liver: respective roles in microsomal tolbutamide, S-mephenytoin, and omeprazole hydroxylations.
Lasker JM; Wester MR; Aramsombatdee E; Raucy JL
Arch Biochem Biophys; 1998 May; 353(1):16-28. PubMed ID: 9578596
[TBL] [Abstract][Full Text] [Related]
19. Functional analysis of phenylalanine residues in the active site of cytochrome P450 2C9.
Mosher CM; Hummel MA; Tracy TS; Rettie AE
Biochemistry; 2008 Nov; 47(45):11725-34. PubMed ID: 18922023
[TBL] [Abstract][Full Text] [Related]
20. Studies of flurbiprofen 4'-hydroxylation. Additional evidence suggesting the sole involvement of cytochrome P450 2C9.
Tracy TS; Marra C; Wrighton SA; Gonzalez FJ; Korzekwa KR
Biochem Pharmacol; 1996 Oct; 52(8):1305-9. PubMed ID: 8937439
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
